Emisphere Technologies, Inc. (OTC BB: EMIS) today announced that the Company is introducing and launching its first commercially available product, oral Eligen® B12 (100 mcg). Oral Eligen® B12 (100 mcg) has been specifically developed to help improve Vitamin B12 absorption and bioavailability with a patented formulation.
“We are very excited that our first product introduction will help to advance the field of nutrition by offering a superior oral formulation to improve Vitamin B12 absorption and bioavailability,” says Michael V. Novinski, President and Chief Executive Officer, Emisphere Technologies. “By partnering with Life Extension, a highly respected company in the nutrient and supplement field, we are confident that we will have the proper marketing and sales infrastructure to allow oral Eligen® B12 (100 mcg) to be successful.”
In a trial with healthy subjects conducted last year, Eligen® B12 (100 mcg) resulted in a ten-fold increase in peak serum B12 blood levels, a two fold improvement in total bioavailability and a reduction in absorption time greater than 90% as compared to standard oral commercial formulations.
“Oral Eligen® B12 (100 mcg) is a scientific breakthrough that will help many individuals by increasing Vitamin B12 levels in the body,” notes Dr. Michael Rothkopf M.D., Director of Atlantic Health’s Metabolic Medicine and Weight Control Center in Morristown, NJ. “It has a different mechanism of action than other available formulations which will also prove to be a benefit.”